467972492
02 Dec 2021
Sweden Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout, Sweden
N/A
Information Technology (IT) Tenders
Procurement News
Click for more details
If you have forgotten your User ID or Password, then please contact the TendersInfo Customercare by Email on customercare@tendersinfo.com.